CancerNetwork previewed which trial data may draw attention when the 2026 ASCO Annual Meeting opens. The pre-meeting embargo lift highlighted cost-effectiveness data from the phase 3 CHALLENGE structured exercise program in resected colon cancer, plus perioperative outcomes in KEYNOTE-B15/EV-304 for urothelial carcinoma and early findings from CHRYSALIS-2 in atypical EGFR-mutant NSCLC. The CHALLENGE economic analysis is central to the preview: a Canadian public payer perspective reported the structured exercise program as dominant over health education materials in a base case, with incremental QALY and cost outcomes reported alongside scenario analyses. For biotech and pharma partners, the bigger takeaway is that ASCO’s front-end narrative is likely to mix efficacy and implementation-relevant endpoints—spanning oncology benefit, perioperative settings, and real-world economic framing.